GlassScriptPhysician profile
Brian Alan Hyman
NPI 1467415315
$7,208.89
in general payments reported to CMS, 2019-2025
53 companies · $708 in 2025
The $708 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,362 · 2020: $632 · 2021: $1,143 · 2022: $1,335 · 2023: $1,340 · 2024: $688 · 2025: $708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,736.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,974.44 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Abbvie INC. | $1,353.02 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $287.48 | 2019-2023 | |
| Acadia Pharmaceuticals INC | $280.45 | 2019-2023 | Nuplazid |
| Lundbeck LLC | $243.67 | 2019-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $233.23 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Celgene Corporation | $229.20 | 2021-2024 | Zeposia |
| Emd Serono, INC. | $227.81 | 2019-2025 | Mavenclad |
| Supernus Pharmaceuticals, INC. | $182.69 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $162.24 | 2019-2024 | Rytary |
| Biogen, INC. | $155.75 | 2019-2025 | Leqembi |
| Mdd US Operations, LLC | $127.64 | 2019-2023 | Gocovri |
| Neurocrine Biosciences, INC. | $126.79 | 2019-2025 | Ingrezza, Ongentys |
| Genentech USA, INC. | $124.44 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Alexion Pharmaceuticals, INC. | $118.75 | 2019-2023 | Ultomiris |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hyman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.